AR
Design armored CAR-T cells with cytokine payloads and resistance mechanisms.
FreedomIntelligence/OpenClaw-Medical-Skills查看
数据与复现
TO
tooluniverse-clinical-trial-design
维护者 FreedomIntelligence · 最近更新 2026年4月1日
Strategic clinical trial design feasibility assessment using ToolUniverse. Evaluates patient population sizing, biomarker prevalence, endpoint selection, comparator analysis, safety monitoring, and regulatory pathways. Creates comprehensive feasibility reports with evidence grading, enrollment projections, and trial design recommendations. Use when planning Phase 1/2 trials, assessing trial feasibility, or designing….
原始来源
FreedomIntelligence/OpenClaw-Medical-Skills
https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/tooluniverse-clinical-trial-design
- 维护者
- FreedomIntelligence
- 许可
- MIT
- 最近更新
- 2026年4月1日
技能摘要
来自 SKILL.md 的关键信息
核心说明
- Systematically assess clinical trial feasibility by analyzing 6 research dimensions. Produces comprehensive feasibility reports ，支持 quantitative enrollment projections，endpoint recommendations，、 regulatory pathway analysis。
- IMPORTANT：Always use English terms in tool calls (drug names，disease names，biomarker names)，even if user writes in another language. Only try original-language terms as fallback if English returns no results. Respond in user's language。
- indication = "EGFR-mutant non-small cell lung cancer" biomarker = "EGFR L858R。
原始文档
SKILL.md 摘录
1. Report-First Approach (MANDATORY)
DO NOT show tool outputs to user. Instead:
- Create
[INDICATION]_trial_feasibility_report.mdFIRST - Initialize with all section headers
- Progressively update as data arrives
- Present only the final report
2. Evidence Grading System
| Grade | Symbol | Criteria | Examples |
|---|---|---|---|
| A | ★★★ | Regulatory acceptance, multiple precedents | FDA-approved endpoint in same indication |
| B | ★★☆ | Clinical validation, single precedent | Phase 3 trial in related indication |
| C | ★☆☆ | Preclinical or exploratory | Phase 1 use, biomarker validation ongoing |
| D | ☆☆☆ | Proposed, no validation | Novel endpoint, no precedent |
3. Feasibility Score (0-100)
Weighted composite score:
- Patient Availability (30%): Population size × biomarker prevalence × geography
- Endpoint Precedent (25%): Historical use, regulatory acceptance
- Regulatory Clarity (20%): Pathway defined, precedents exist
- Comparator Feasibility (15%): Standard of care availability
- Safety Monitoring (10%): Known risks, monitoring established
适用场景
- Plan early-phase trials (Phase 1/2 emphasis)。
- Need enrollment feasibility assessment。
- Design biomarker-selected trials。
- 评估 endpoint strategies。
不适用场景
- Do not rely on this catalog entry alone ，用于 installation 或 maintenance details。
相关技能
相关技能
AR
数据与复现
arxiv-search
Search arXiv physics, math, and computer science preprints using natural language queries. Powered by Valyu semantic sea…
FreedomIntelligence/OpenClaw-Medical-Skills查看
AU
Autonomous oncology research agent: literature mining, trial matching, biomarker analysis, and treatment hypothesis gene…
FreedomIntelligence/OpenClaw-Medical-Skills查看
BI
Preprocesses cell-free DNA sequencing data including adapter trimming, alignment optimized for short fragments, and UMI-…
FreedomIntelligence/OpenClaw-Medical-Skills查看